Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy

被引:5
|
作者
Fang, Rui [1 ,2 ]
Wang, Heng [1 ,2 ]
Li, Yang [1 ,2 ]
Liu, Yue-Ming [1 ,2 ]
Wei, Wen-Bin [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Beijing Tongren Hosp, Beijing 100730, Peoples R China
[2] Capital Med Univ, Beijing 100730, Peoples R China
[3] Beijing Tongren Eye Ctr, Beijing, Peoples R China
[4] Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing, Peoples R China
[5] Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China
[6] Minist Ind & Informat Technol, Med Artificial Intelligence Res & Verificat Lab, Beijing, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Uveal melanoma; Plaque radiotherapy; Tumor regression; Prognosis; CHOROIDAL MELANOMAS;
D O I
10.1186/s12886-021-01898-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Tumor regression of uveal melanomas (UMs) after radiotherapy has been reported as a valuable prognostic factor for metastasis and metastatic death. But its effect on prognosis is questionable. The purpose of this study was to summarize the regression features of uveal melanoma after iodine-125 plaque brachytherapy and the relationship with prognosis. Methods Adult uveal melanoma patients who only received iodine-125 plaque brachytherapy between December 2009 and March 2018 at the Beijing Tongren Hospital, Capital Medical University were enrolled in this study. The regression rate was calculated as the percent change in tumor height, and each eye was classified for four main regression patterns: Decrease (D), Stable (S), Others (O), and Increase (I), according to the trend of height change. Statistical analysis was performed using one-way ANOVA and chi-square test, univariate and multivariate logistic regression, and Kaplan-Meier analysis. Results A total of 139 patients was included in the study. The median follow-up was 35 months. Regression patterns status was pattern D in 65 tumors (46.8%), pattern S in 50 tumors (36.0%), pattern O in 6 tumors (4.3%), and pattern I in 18 tumors (12.9%). Reductions of tumor mean height for each follow-up visit were 5.26% (3 months), 10.66% (6 months), 9.37% (12 months), and 14.68% (18 months). A comparison (D vs. S vs. O vs. I) revealed the preoperative height of pattern I was significantly lower than the pattern D, S and O (mean: 7.24 vs. 7.30 vs. 6.77 vs. 5.09 mm, respectively; P = 0.037). LBD (largest basal diameter) was strongly associated with the metastasis (P = 0.03). However, an association between the tumor regression and subsequent melanoma-related metastasis and mortality could not be confirmed (P = 0.66 and P = 0.27, respectively). The tumor regression rate increased with increasing tumor height (P = 0.04) and decreased with increasing of LBD (P = 0.01). Conclusion Our study showed a lack of association between the prognosis and the regression of uveal melanomas following I-125 plaque radiotherapy. The LBD and original height of the tumor have predictive value in tumor regression rate, and LBD was positively associated with metastasis.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Extrascleral extension of choroidal melanoma after iodine-125 brachytherapy treatment: a case series
    Hamzah Mustak
    Christopher Lo
    Liza M. Cohen
    Annie Tran
    Robert Almanzor
    Tara A. McCannel
    Robert A. Goldberg
    Daniel B. Rootman
    Eye, 2023, 37 : 249 - 255
  • [42] Primary orbital melanoma treated with iodine-125 plaque radiotherapy
    De Potter, Patrick
    Levecq, Laurent
    Godfraind, Catherine
    Renard, Laurette
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (05) : 864 - 866
  • [43] Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma
    Caminal, J. M.
    Padron-Perez, N.
    Arias, L.
    Masuet-Aumatell, C.
    Gutierrez, C.
    Piulats, J. M.
    Pera, J.
    Catala, J.
    Rubio, M. J.
    Arruga, J.
    EYE, 2016, 30 (06) : 833 - 842
  • [44] Extrascleral extension of choroidal melanoma after iodine-125 brachytherapy treatment: a case series
    Mustak, Hamzah
    Lo, Christopher
    Cohen, Liza M.
    Tran, Annie
    Almanzor, Robert
    McCannel, Tara A.
    Goldberg, Robert A.
    Rootman, Daniel B.
    EYE, 2023, 37 (02) : 249 - 255
  • [45] Intravitreal Aflibercept for Radiation Retinopathy After Iodine-125 Brachytherapy for the Treatment of Choroidal Melanoma
    Kothari, Nikisha
    McCannel, Tara
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [46] Attenuation of Iodine-125 Radiation With Vitreous Substitutes in the Treatment of Uveal Melanoma
    Oliver, S. C.
    Leu, M. Y.
    Lee, S. P.
    McCannel, T. A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [47] Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma
    Detorakis, ET
    Engstrom, RE
    Wallace, R
    Straatsma, BR
    OPHTHALMOLOGY, 2005, 112 (03) : 505 - 510
  • [48] Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma
    Mruthyunjaya, Prithvi
    Seider, Michael I.
    Stinnett, Sandra
    Schefler, Amy
    OPHTHALMOLOGY, 2017, 124 (10) : 1532 - 1539
  • [49] 23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity
    McCannel, Tara A.
    Kamrava, Mitchell
    Demanes, Jeffrey
    Lamb, James
    Bartlett, John D.
    Almanzor, Robert
    Chun, Melissa
    McCannel, Colin A.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 254 (12) : 2461 - 2467
  • [50] 23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity
    Tara A. McCannel
    Mitchell Kamrava
    Jeffrey Demanes
    James Lamb
    John D. Bartlett
    Robert Almanzor
    Melissa Chun
    Colin A. McCannel
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254 : 2461 - 2467